Physician profile
Arthur B Boyd
NPI 1124689195
$5,798.74
in general payments reported to CMS, 2019-2025
16 companies · $5,301 in 2025
The $5,301 reported for 2025 was more than what 92% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.84 · 2021: $22.69 · 2024: $458 · 2025: $5,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,668 · Food and Beverage: $2,047 · Entertainment: $44.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,667.73 |
| Food and Beverage | $2,047.13 |
| Entertainment | $44.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,102.43 | 2025 | Proclaim |
| Si-Bone, INC. | $1,200.57 | 2025 | |
| Stryker Corporation | $940.78 | 2025 | Mild Device Kit, Optablate |
| Foundation Fusion Solutions, LLC | $414.66 | 2025 | |
| Medtronic, INC. | $327.39 | 2021-2025 | Intellis Adaptivestim, Primeadvanced Surescan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.72 | 2020-2025 | Relistor |
| Spinal Simplicity, LLC | $198.38 | 2025 | Ha Minuteman G3-R |
| Glaxosmithkline, LLC. | $112.95 | 2024 | Jemperli |
| Boston Scientific Corporation | $79.50 | 2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $56.52 | 2025 | Belbuca, Xtampza |
| Nalu Medical, INC. | $35.88 | 2025 | Nalu Neurostimulation System |
| Azurity Pharmaceuticals, INC. | $18.93 | 2025 | Horizant |
| Novo Nordisk INC | $18.49 | 2024 | Rybelsus, Ozempic |
| Globus Medical, INC. | $17.97 | 2025 | Senza |
| Valinor Pharma, LLC | $15.10 | 2024 | Movantik |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $13.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.